The Arcview
Group

A finance firm for a plant that used to get people arrested

Walk into an Arcview investor forum today and you will find spreadsheets, term sheets, and people in blazers arguing about gross margins. The product they are valuing happens to be cannabis. A decade ago that sentence would have ended in handcuffs. Now it ends in a cap table.

The Arcview Group sits at the center of legal cannabis the way a stock exchange sits at the center of a market - not by growing anything, but by deciding who gets funded, who gets quoted, and who gets a seat in the room. It is an investor network, a research desk, a brokerage, and a consultancy, stitched into what the company calls the industry's first full-scale ecosystem. The unglamorous truth is that an industry cannot scale on conviction alone. It needs capital, numbers, and someone willing to put their name on both.

Plenty of passion, almost no plumbing

By the late 2000s the cannabis movement had no shortage of believers. What it lacked was infrastructure. There was no Bloomberg terminal for weed, no syndicate of accredited investors, no trusted number a journalist could cite without a wink. Entrepreneurs had products and prison risk in equal measure; investors had curiosity and no safe way to act on it.

That gap was the whole problem. Activism could change laws, eventually. But laws change faster when there is a legitimate, profitable industry lobbying alongside the protesters - an industry that pays taxes, hires lawyers, and shows up with a P&L. Someone had to build the connective tissue between idealists and capital. Ironically, the people best positioned to do it were two activists who had spent years arguing that money was beside the point.

Two activists who decided protest signs don't scale

Troy Dayton had been in the fight since 1995 - first volunteer for the Marijuana Policy Project, co-starter of Students for a Sensible Drug Policy. Steve DeAngelo was a cannabis entrepreneur and reform veteran with the rare gift of making the case to people in suits. In February 2010 they launched Arcview on a contrarian wager: that the surest path to legalization ran through the capital markets, not just the courtroom.

DeAngelo became the company's first investor before it formally launched, which tells you how much of this was faith and how little was a guaranteed return. The same pair would go on to co-found the National Cannabis Industry Association, because if you are going to professionalize an industry you may as well give it a trade group too. Their bet was simple to state and hard to execute: make cannabis investable, and the rest follows.

Four businesses wearing one trench coat

Arcview is less a single product than a stack. The Arcview Investor Network connects accredited members - at peak, 600-plus of them - with vetted deal flow, turning scattered curiosity into organized checks. Arcview Capital adds broker-dealer services, private placements, and member-managed funds. Arcview Market Research produces the data the rest of the industry quotes. Arcview Consulting helps operators actually scale once the money lands.

Layered on top are events, education, and equity work - including social-justice reporting and a Women's Inclusion Network. The company describes itself as built "with social justice and responsibility at its core," which in cannabis is not decoration. The same prohibition that criminalized the plant also disproportionately jailed the communities now watching others get rich off it. Arcview's bet is that the industry's legitimacy depends on not forgetting that.

The receipts, not the rhetoric

Conviction is cheap; track records are not. Investors in the Arcview network have deployed more than $270 million into over 200 cannabis companies. Some of those early bets aged well: MJ Freeway became Akerna, Tokyo Smoke was acquired by Canopy Growth, and Eaze grew into one of cannabis delivery's best-known names. Forbes has listed Arcview among the top financial firms in the sector. When Bloomberg, CNN, Forbes, and Fortune needed a cannabis market number, Arcview's research is what they reached for.

The research arm is arguably the firm's quietest flex. Numbers from a firm with a stake in the outcome should be read with a raised eyebrow - and yet Arcview's projections, produced with data partner BDS Analytics, became the industry standard precisely because skeptics kept finding them useful. The chart below shows the kind of growth those reports were tracking.

Profit, with the receipts of who paid for prohibition

Arcview's framing is unusual for a finance firm: social justice is positioned at the core, not the appendix. The company runs equity reporting and a Women's Inclusion Network, and its founders have argued that the industry's long-term legitimacy depends on repairing the harms of the drug war, not just monetizing its end. It is easy to be cynical about a values statement attached to a brokerage. It is harder to ignore that the same people built the trade association lobbying for the industry's right to exist.

The mission, stripped of slogans, is to be the trusted nexus - the place where investors, operators, entrepreneurs, and community meet without anyone getting fleeced or arrested. That is a modest-sounding goal that happens to require a brokerage license, a research methodology, and a decade of relationships to pull off.

When the suits arrived, the scaffolding was already up

Cannabis is no longer a fringe bet. Wall Street has noticed, institutional money is circling, and federal policy keeps inching toward something investable nationwide. When that fully arrives, the firms that built the early infrastructure - the deal networks, the research standards, the consultancies - will have a head start measured in years. Arcview spent a decade laying that scaffolding while it was still unfashionable, and occasionally illegal, to do so.

The competition is real now: Casa Verde, Merida, Poseidon, and research rivals like New Frontier Data all want the same room. That is what success looks like in a market you helped legitimize - it gets crowded. The question for Arcview is whether being early stays an advantage once everyone shows up.

Which brings us back to that investor forum. The blazers, the spreadsheets, the gross-margin arguments over a plant that was contraband a decade ago. None of that ordinary, slightly boring professionalism happened by accident. Someone had to make cannabis investable first. Arcview did - and the proof is that the room no longer finds it remarkable.

Five things that didn't fit anywhere else